5. Drooger JC, van der Padt A, Sleijfer S, Jager A. Denosumab in breast cancer treatment. Eur J Pharmacol. 2013;717:12-9
|
|
- Emma Sanders
- 8 years ago
- Views:
Transcription
1 PUBLICATIONS AGNES JAGER: 1. Milne RL, Herranz J, Michailidou K, Jager A,. Malats N, Easton DF. A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. Hum Mol Genet. 2014;23: M. Kriege M, Hollestelle A, Jager A, Huijts PEA, Berns EM, Sieuwerts AM, Meijer-van Gelder ME, Collée JM, Devilee P, Hooning MJ, Martens JWM, Seynaeve S. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. Br J Cancer Jun 10. [Epub ahead of print] 3. Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens J, O'Connor MJ, Vrieling H, Hoeijmakers JH, Jonkers J, Kanaar R, de Winter J, Vreeswijk M, Jager A, van Gent DC. Ex vivo assessment of Homologous Recombination reveals different modes of BRCA gene silencing in p rimary breast tumors Clinical Cancer research 2014; Epub ahead of print 4. Heemskerk BAM, Menke-Pluijmers MBE, Jager A, Tilanus-Linthorst MMA, Koppert LB, Obdeijn IMA, van Deurzen CHM, Collee JM, Seynaeve C, Hooning MJ. Substantial breast cancer risk-reduction and improved survival after bilateral mastectomy in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol 2013;24: Drooger JC, van der Padt A, Sleijfer S, Jager A. Denosumab in breast cancer treatment. Eur J Pharmacol. 2013;717: Georgieva RD, Obdeijn IM, Jager A, Hooning MJ, Tilanus-Linthorst MM, van Deurzen CH. Breast fineneedle aspiration cytology performance in the high-risk screening population: A study of BRCA1/BRCA2 mutation carriers. Cancer Cytopathol. 2013;121: Binkhorst L, Mathijssen RH, van Herk-Sukel MP, Bannink M, Jager A, Wiemer EA, van Gelder T. Unjustified prescribing of CYP2D6 inhibiting SSRI's in women treated with tamoxifen. Breast Cancer Res Treat Jun;139(3): Michailidou K, Hall P, Gonzalez-Niera A,. Jager A,. Benitez J, Easton DF. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet : Bojesen SE, Pooley KA, Johnatty SE, Jager A, Chenevix-Trench G, Dunning AM. Multiple independent TERT variants are associated with telomere length and breast cancer risk. Nat Genet : Rakha EA, Tan PH, Shaaban A, Tse GM, Esteller FC, van Deurzen CH, Purnell D, Stotter A, Chan T, Yamaguchi R, Dodwell D, Jager A, Soler MT, Juneinah E, Plaza ML, Hodi Z, McCulloch T, Lee AH, Ellis IO. Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. Breast. 2013;22:
2 11. Vencken PMLH, Kriege M, Hooning M, Menke-Pluymers MB, Heemskerk A, van Doorn H, Collée, M, Jager A, van Montfort C, Burger CW, Seynaeve CM. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/2 mutation carriers; implications for counselling. Cancer 2013;119: Ding YC, McGuffog L, Healey S,, Jager A,., Antoniou AC, Neuhausen SL; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012;21: Warren H, Dudbridge F, Fletcher O, Jager A,.Peto J, Dos-Santos-Silva I. 9q31.2-rs as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2012;21: Fasching PA, Pharoah PD, Cox A,.Jager A,, Easton DF, Schmidt MK. The role of genetic breast cancer susceptibility loci as prognostic factors. The role of genetic breast cancer susceptibility loci as prognostic factors. Hum Mol Genet. 2012;21: Vos de FYFL, van Laarhoven HMW, Laven JSE. Themmen APN, Beex LVAM, Sweep CGJ, Seynaeve CM, Jager A. Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline. Crit Rev Oncol Hematol 2012;84: de Raaf PJ, Sleijfer S, Lamers C, Jager A, Gratama JW, van der Rijt CCD. Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study. Cancer. 2012;118: Oldenmenger WH, Lieverse PJ, Janssen PJ, Taal W, van der Rijt CC, Jager A. Efficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioids. Support Care Cancer. 2012;20: Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Moghaddam-Helmantel IM, de Jonge E, Jager A, Seynaeve CM, van Schaik RH, Verweij J, Mathijssen RH. Effects of CYP induction by Rifampicin on Tamoxifen Exposure. Clin Pharmacol Ther. 2012;92: Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CH, Bontenbal M, Collee JM, Menke-Pluijmers MB, Martens JW, Seynaeve C The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer 2012;118: Ramus SJ, Kartsonaki C, Gayther SA,. Jager A,..., Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2011;103: Manders P, Pijpe A, Hooning MJ, Jager A,.van Leeuwen FE, Rookus MA. Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2011;126:
3 22. Osorio A, Milne RL, Alonso R,... Jager A,..., Radice P, Benítez J; CIMBA. Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. Br J Cancer. 2011;104: Yang XR, Chang-Claude J, Goode EL, Jager A,., Sherman ME, Garcia-Closas M. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst. 2011;103: van Deurzen CH, Lee AH, Gill MS, Menke-Pluijmers MB, Jager A, Ellis IO, Rakha EA. Metaplastic breast carcinoma: tumor histogenesis or dedifferentiation? J Pathol. 2011;224: Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, Hooning MJ, Berns EM, Jager A, Collée M, Burger CW, Seynaeve C. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first line chemotherapy compared with sporadic ovarian cancer patients. Annals of Oncology 2011;22: Antoniou AC, Beesley J, McGuffog L,. Jager A,.., Chenevix-Trench G, Easton DF; CIMBA. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010;70: Antoniou AC, Wang X, Fredericksen ZS, Jager A,..., Easton DF, Couch FJ. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptornegative breast cancer in the general population. Nat Genet. 2010;42: Broeks A, Schmidt MK, Sherman ME, Jager A,., Pharoah PD, Garcia-Closas M. for the Breast Cancer Association Consortium. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: Findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2011;20: Gaudet MM, Kirchhoff T, Green T, Jager A,., Spurdle AB, Chenevix-Trench G. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet ;6:e Johnatty SE, Couch FJ, Fredericksen Z,. Jager A,., Easton DF, Chenevix-Trench G; Breast Cancer Association Consortium and Consortium of Investigators of Modifiers of BRCA1/2. No evidence that GATA3 rs SNP modifies breast cancer risk. Breast Cancer Res Treat. 2009;117: Jager A, Verweij J, Sleijfer S. Adjuvant chemotherapy in older breast cancer patients. Nature reviews clinical oncology. 2009;6: Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MBE, Bartels CCM, Tilanus- Linthorst MMA, Blom J, Huijskens E, Jager A, van den Ouweland A, van Geel B, Hooning MJ, Brekelmans CTM, Klijn JGM. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology. 2009;27:
4 33. Jager A, Sleijfer S, van der Rijt CCD. Pathogenesis of cancer related fatigue: Could increased proinflammatory cytokine activity be the common denominator? European Journal of Cancer 2008;44: Juffermans NP, Jager A, Kersten MJ, van Oers MH, Hommes DW. Epstein-Barr-virus-gerelateerde lymfomen bij patiënten met inflammatoire darmziekte. Nederlands Tijdschrift voor Geneeskunde 2005;149: de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CDA, Nijpels G, Bouter LM, Heine RJ. Verhoogde glucoseconcentraties in nuchtere toestand en na glucosebealsting: risicofactoren van het otstaan van diabetes mellitus type 2; uitresultaten van de Hoorn-studie. Nederlands Tijdschrift voor geneeskunde 2003;147: Patel JN, Jager A, Schalkwijk C, Corder R, Douthwaite JA, Yudkin JS, Coppack SW, Stehouwer CDA. Effects of tumor necrosis factor- in the human forearm: blood flow and endothelin-1 release. Clinical Science 2002;103: Spijkerman AW, Dekker JM, Nijpels G, Jager A, Kostense PJ, van Hinsbergh VWM, Bouter LM, Heine RJ, Stehouwer CDA. Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: The Hoorn Study. European Journal of Clinical Investigation 2002;32: Jager A, van Hinsbergh VWM, Kostense PJ, Nijpels G, Emeis JJ, Dekker JM, Heine RJ, Bouter LM, Stehouwer CDA. C-reactive protein and soluble vascular cellular adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arteriosclerosis, Thrombosis and Vascular Biology 2002; 22: Becker A, van Hinsbergh VWM, Jager A, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA. Why is a high plasma level of soluble intercellular adhesion molecule-1 related to cardiovascular mortality in diabetic and nondiabetic subjects? European Journal of Clinical Investigation 2002;32: de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CDA, Nijpels G, Bouter LM, Heine RJ. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 2001;285: Jager A, van Hinsbergh VWM, Nijpels G, Emeis JJ, Dekker JM, Heine RJ, Bouter LM, Stehouwer CDA. Prognostic implications of retinopathy and/or endothelial dysfunction in non-insulin-dependent diabetic subjects with microalbuminuria. Nephrology, Dialysis and Transplantation, : Jager A, Kostense PJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CDA. Serum homocysteine levels are associated with the development of (micro)albuminuria: Follow-up of the Hoorn Study. Arteriosclerosis, Thrombosis and Vascular Biology 2001;21:
5 43. Smulders YM, Jager A, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA. Impaired cardiovascular autonomic function is associated with (micro-)albuminuria in elderly Caucasian subjects with impaired glucose tolerance or NIDDM: The Hoorn Study. Diabetes Care 2000;23: Becker A, van Hinsbergh VWM, Kostense PJ, Jager A, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA. Serum homocysteine is weakly associated with von Willebrand factor and soluble vascular cell adhesion molecule 1, but not with C-reactive protein in type 2 diabetic and nondiabetic subjects; the Hoorn Study. European Journal of Clinical Investigation 2000;30: Jager A, van Hinsbergh VWM, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CDA. Increased levels of soluble vascular cell adhesion molecule 1 (svcam-1) are associated with risk of cardiovascular mortality in non-insulin-dependent diabetes mellitus: The Hoorn Study. Diabetes 2000;49: Jager A, Stehouwer CDA. Early detection of diabetic and non-diabetic subjects with increased cardiovascular risk: new risk indicators. Heart and Metabolism 1999;5: Schalkwijk CG, Ligtvoet N, Twaalfhoven H, Jager A, Blaauwgeers HGT, Schlingermann RO, Tarnow L, Parving H-H, Stehouwer CDA, van Hinsbergh VWM. Amadori-albumin in type I diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy and localization in retinal capillaries. Diabetes 1999;48: Jager A, van Hinsbergh VWM, Kostense PJ, Nijpels G, Yudkin JS, Emeis JJ, Dekker JM, Heine RJ, Bouter LM, Stehouwer CDA. Von Willebrand factor, C-reactive protein and 5-year mortality in diabetic and nondiabetic subjects. The Hoorn Study. Arteriosclerosis, Thrombosis and Vascular Biology, 1999 ;19: Jager A, Kostense PJ, Ruhe HG, Nijpels G, Dekker JM, Bouter LM, Stehouwer CDA. Microalbuminuria and peripheral arterial disease are independent predictors of all-cause and cardiovascular mortality, especially among hypertensive subjects: Five-year follow-up of the Hoorn Study. Arteriosclerosis, Thrombosis and Vascular Biology 1999;19: Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jacobs C, Bouter LM, Donker AJM, Stehouwer CDA. Serum homocysteine level and protein intake are related to risk of (micro) albuminuria: a population based study. Kidney International 1998;54: Jager A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA. Microalbuminuria is strongly associated with NIDDM and hypertension but not with the insulin resistance syndrome: The Hoorn Study. Diabetologia 1998;41: Stehouwer CDA, Jager A, Donker AJM. Capita Selecta: Microalbuminurie bij essentiële hypertensie: van betekenis voor het aanwijzen van patiënten met een hoog risico voor complicaties. Nederlands Tijdschrift voor Geneeskunde 1997;34:
6 53. Dolman KM, Jager A, Sonnenberg A, Kr. von dem Borne AEG, Goldschmeding R. Proteolysis of classic anti neutrophil cytoplasmic autoantibodies (C-ANCA) by neutrophil proteinase 3. Clinical Experimental Immunology 1995;101:8-12 6
How To Know If You Have Microalbuminuria
3 PREVALENCE AND PREDICTORS OF MICROALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A CROSS-SECTIONAL OBSERVATIONAL STUDY Dr Ashok S Goswami *, Dr Janardan V Bhatt**; Dr Hitesh Patel *** *Associate
More informationVictims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years
Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957
More informationGenetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS -
Genetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS - January 2005 SCIENTIFIC BACKGROUND Breast cancer is considered to be one of the most prevalent cancer in women. The overall
More informationBRCA1 and BRCA2. BRCA1 and BRCA2 Clinician Guide KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS
BRCA1 and BRCA2 BRCA1 and BRCA2 Clinician Guide KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS BRCA1 and BRCA2 Breast cancer is the most common cancer in women, diagnosed in
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationHEREDITARY BRCA1. Faulty gene INFORMATION LEAFLET. How Do I Reduce My Risk?
HEREDITARY BREAST CANCER BRCA1 Faulty gene INFORMATION LEAFLET How Do I Reduce My Risk? Page 1 CONTENTS Part A 1 What is BRCA1 2 How does BRCA1 affect a person s risk of cancer? 3Testing for BRCA1 4Benefits
More informationCardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005
Cardiovascular Disease Risk Factors Part XII By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005 As we approach the end of our extended series on cardiovascular disease risk factors,
More informationRisk Assessment and Screening Tools November 17, 2010
Risk Assessment and Screening Tools November 17, 2010 Cecelia Bellcross Posted in the Resource Repository at: http://www.resourcerepository.org/documents/2073/riskassessmentandscreeningtool s/ Cecelia
More informationProgress and Prospects in Ovarian Cancer Screening and Prevention
Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian
More informationHow To Decide If You Should Get A Mammogram
American Medical Women s Association Position Paper on Principals of Breast Cancer Screening Breast cancer affects one woman in eight in the United States and is the most common cancer diagnosed in women
More informationDrug Treatment in Type 2 Diabetes with Hypertension
Hypertension is 1.5 2 times more prevalent in Type 2 diabetes (prevalence up to 80 % in diabetic subjects). This exacerbates the risk of cardiovascular disease by ~ two-fold. Drug therapy reduces the risk
More informationHereditary Ovarian cancer: BRCA1 and BRCA2. Karen H. Lu MD September 22, 2013
Hereditary Ovarian cancer: BRCA1 and BRCA2 Karen H. Lu MD September 22, 2013 Outline Hereditary Breast and Ovarian Cancer (HBOC) BRCA1/2 genes How to identify What it means to you What it means to your
More informationRecommendations for the management of early breast cancer
Recommendations for the management of early breast cancer in women with an identified BRCA1 or BRCA2 gene mutation or at high risk of a gene mutation FEBRUARY 2014 Incorporates published evidence to August
More informationMolecular markers and clinical trial design parallels between oncology and rare diseases?
Molecular markers and clinical trial design parallels between oncology and rare diseases?, Harriet Sommer Institute for Medical Biometry and Statistics, University of Freiburg Medical Center 6. Forum Patientennahe
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationGenetic Testing for CHEK2 Mutations for Breast Cancer
Genetic Testing for CHEK2 Mutations for Breast Cancer Policy Number: 2.04.133 Last Review: 8/2015 Origination: 8/2015 Next Review: 8/2016 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationRadiation exposure and the risk of breast cancer in BRCA 1/2 mutation carriers
Radiation exposure and the risk of breast cancer in BRCA 1/2 mutation carriers "Bathsheba bathing" by Rembrandt, 1654 Flora E. van Leeuwen Anouk Pijpe Department of Epidemiology Radiation exposure and
More informationThe Need for a PARP in vivo Pharmacodynamic Assay
The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235
More informationKIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
More informationGUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*
71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the
More informationYour Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationNatalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia
Pathogenesis of Dengue Natalia Taborda Vanegas Doc. Sci. Student Immunovirology Group Universidad de Antioquia Infection process Epidermis keratinocytes Dermis Archives of Medical Research 36 (2005) 425
More informationGenetic Epidemiology Core Laboratory
2012 CGM Report Genetic Epidemiology Core Laboratory 卓 越 成 員 Remarkable member Wei J. Chen 陳 為 堅 Professor/ / EDUCATION AND POSITION HELD Bachelor of Medicine, College of Medicine, National Taiwan University,
More informationAlbuminuria as a Marker of the Risk of Developing Type 2 Diabetes in Non- Diabetic Aboriginal Australians
Albuminuria as a Marker of the Risk of Developing Type 2 Diabetes in Non- Diabetic Aboriginal Australians Zhiqiang Wang 1 and Wendy E Hoy 1 Centre for Chronic Disease, Department of Medicine, Central Clinical
More informationDiabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW
Diabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW IT`S HARD TO GIVE GENERAL ADVICE! ``The Elderly`` Heterogeneous group ;widely varying
More informationPharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
More informationSummary and conclusions. Chapter 8. Summary and conclusions
Summary and conclusions Chapter 8 Summary and conclusions 153 Chapter 8 154 Summary and conclusions Summary This thesis describes an experimental study in healthy MZ and same-sex DZ twins and siblings
More informationCellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
More informationProportion of patients with invasive breast cancer in whom ER, PR and/or
1.1.a. Proportion of patients with invasive breast cancer in whom ER, PR and/or HER2 status assessment were performed 1.1.b. Proportion of patients with invasive breast cancer in whom systemic treatment
More informationOne of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J.
Hormone Therapy in Postmenopausal Women With Breast Cancer * William J. Gradishar, MD ABSTRACT *Based on a presentation given by Dr Gradishar at a roundtable symposium held in Baltimore on June 28, 25.
More informationBreast Cancer Educational Program. June 5-6, 2015
Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:
More informationBREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader. Two years ago, I was working as a bedside nurse. One of my colleagues felt
Ali A. Kader, S. (2010). Breast cancer awareness for women and men. UCQ Nursing Journal of Academic Writing, Winter 2010, 70 76. BREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader Two years
More informationUnderstanding Hereditary Breast and Ovarian Cancer. Maritime Hereditary Cancer Service
Understanding Hereditary Breast and Ovarian Cancer Maritime Hereditary Cancer Service General Information Cancer is very common. About one in three (33%) people are diagnosed with some form of cancer during
More information25-hydroxyvitamin D: from bone and mineral to general health marker
DIABETES 25 OH Vitamin D TOTAL Assay 25-hydroxyvitamin D: from bone and mineral to general health marker FOR OUTSIDE THE US AND CANADA ONLY Vitamin D Receptors Brain Heart Breast Colon Pancreas Prostate
More informationAutoimmunity and immunemediated. FOCiS. Lecture outline
1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic
More informationProtocol: Alcohol consumption and diabetes risk factors: a meta-analysis of interventional studies
Protocol: Alcohol consumption and diabetes risk factors: a meta-analysis of interventional studies Version: 1 Date: Study team: C Mary Schooling, CUNY School of Public Health at Hunter College, 2180 Third
More informationTHE RISK DISTRIBUTION CURVE AND ITS DERIVATIVES. Ralph Stern Cardiovascular Medicine University of Michigan Ann Arbor, Michigan. stern@umich.
THE RISK DISTRIBUTION CURVE AND ITS DERIVATIVES Ralph Stern Cardiovascular Medicine University of Michigan Ann Arbor, Michigan stern@umich.edu ABSTRACT Risk stratification is most directly and informatively
More informationThe Genetics of Early- Onset Breast Cancer. Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine
The Genetics of Early- Onset Breast Cancer Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine All cancers are genetic BUT Not all cancers are hereditary
More informationPlatelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D.
Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel Kiyuk Chang, M.D., Ph.D. Cardiovascular Center & Cardiology Division Seoul St. Mary s Hospital The Catholic University
More informationDiabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
More informationUsefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancers
J. Appl. Genet. 44(3), 2003, pp. 419-423 Short communication Usefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancers Bohdan GÓRSKI,
More informationGenetic Testing for Tamoxifen Treatment. Medical Benefit Effective Date: 10/01/12 Next Review Date: 07/13 Preauthorization* No Review Dates: 07/12
Protocol Genetic Testing for Tamoxifen Treatment (20451) Medical Benefit Effective Date: 10/01/12 Next Review Date: 07/13 Preauthorization* No Review Dates: 07/12 The following Protocol contains medical
More informationThe WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?
AACE 23 rd Annual Scientific and Clinical Congress (2014) Syllabus Materials: The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? JoAnn E. Manson, MD, DrPH, FACP, FACE Chief, Division
More informationHow To Determine The Prevalence Of Microalbuminuria
Research Journal of Pharmaceutical, Biological and Chemical Sciences Prevalence of Microalbuminuria in relation to HbA1c among known Type2 Diabetic Patients in Puducherry population Muraliswaran P 1 *,
More informationPreventing Breast, Ovarian Cancer in BRCA Carriers: Rational of Prophylactic Surgery and Promises of Surveillance
Annals of Surgical Oncology, 11(12):1030 1034 DOI: 10.1245/ASO.2004.09.910 Editorial Preventing Breast, Ovarian Cancer in BRCA Carriers: Rational of Prophylactic Surgery and Promises of Surveillance Niki
More informationCan Common Blood Pressure Medications Cause Diabetes?
Can Common Blood Pressure Medications Cause Diabetes? By Nieske Zabriskie, ND High blood pressure, or hypertension, is a major risk factor for cardiovascular disease. In the United States, approximately
More informationSommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of
More informationFlorida Breast Health Specialists Breast Cancer Information and Facts
Definition Breast cancer is a cancer that starts in the tissues of the breast. There are two main types of breast cancer: Ductal carcinoma starts in the tubes (ducts) that move milk from the breast to
More informationNumber 12.04.516 Effective Date August 11, 2015 Revision Date(s) Replaces 2.04.133 (not adopted)
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDI HISTORY Genetic Testing for CHEK2 Mutations for Breast Cancer Number 12.04.516
More informationMULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
More informationHereditary Breast Cancer. Nicole Kounalakis, MD Assistant Professor of Surgery University of Colorado Medical Center
Hereditary Breast Cancer Nicole Kounalakis, MD Assistant Professor of Surgery University of Colorado Medical Center Outline Background Assessing risk of patient Syndromes BRCA 1,2 Li Fraumeni Cowden Hereditary
More informationAbstract Introduction. Aim of the study. Conclusion. Patients and methods. Keywords. Results. R. Abo El Hassan 1, M. Moneer 2
Original Study Outcome of HER2 positive luminal operable breast cancer in comparison with outcome of other operable luminal breast cancer patients: Long follow-up of single center randomized study R. Abo
More informationChemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015
Chemobrain Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015 Terminology Chemotherapy-associated cognitive dysfunction Post-chemotherapy cognitive impairment Cancer treatment-associated cognitive
More informationSIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon
SIOG Guidelines Update 2014 Prostate Cancer Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou
More informationNancy E. Davidson, MD Johns Hopkins University. Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationMicroalbuminuria: An increasingly recognized risk factor for CVD
Microalbuminuria: An increasingly recognized risk factor for CVD Long known to be associated with kidney disease, the importance of protein in the urine is now becoming recognized as a sensitive, accessible
More informationIs Insulin Effecting Your Weight Loss and Your Health?
Is Insulin Effecting Your Weight Loss and Your Health? Teressa Alexander, M.D., FACOG Women s Healthcare Associates www.rushcopley.com/whca 630-978-6886 Obesity is Epidemic in the US 2/3rds of U.S. adults
More informationScreening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement
Screening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement Rebecca Ferrini, MD, Elizabeth Mannino, MD, Edith Ramsdell, MD and Linda Hill, MD, MPH Burden
More informationHereditary Multifocal Breast Cancer. Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center
Hereditary Multifocal Breast Cancer Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center CASE STUDY 30 year old Ashkenazi Jewish woman Nulliparous Felt
More informationDal germinale al somatico nella identificazione di tumori ereditari
Modena 18-19 novembre 2010 Dal germinale al somatico nella identificazione di tumori ereditari Laura Ottini Tendencies to develop cancer can be inherited Fletcher & Houlston, 2010 Cancer is a genetic disease
More informationIn many diabetes units, people with type
Renal Microalbuminuria: Screening and management in type 2 diabetes Julia Arundale Introduction In many diabetes units, patients with type 1 or type 2 diabetes are screened for proteinuria. Screening for
More informationSupport Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine
Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine January 27, 2009 Dear Professors (representative) of departments, Subject:
More informationtreatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
More informationCost-effectiveness of predictive genetic tests for familial breast and ovarian cancer
Cost-effectiveness of predictive genetic tests for familial breast and ovarian cancer NIKKI BREHENY, ELIZABETH GEELHOED, JACK GOLDBLATT & PETER O LEARY Abstract Aim: To examine the relative cost-effectiveness
More informationBRCA in Men. Mary B. Daly,M.D.,Ph.D. June 25, 2010
BRCA in Men Mary B. Daly,M.D.,Ph.D. June 25, 2010 BRCA in Men Inheritance patterns of BRCA1/2 Cancer Risks for men with BRCA1/2 mutations Risk management recommendations for men with BRCA1/2 mutations
More informationNon Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
More informationOvarian Cancer Genetic Testing: Why, When, How?
Ovarian Cancer Genetic Testing: Why, When, How? Jeffrey Dungan, MD Associate Professor Division of Clinical Genetics Department of Obstetrics & Gynecology Northwestern University Feinberg School of Medicine
More informationBody Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ
Body Composition & Longevity Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ LONGEVITY Genetic 25% Environmental Lifestyle Stress 75% BMI >30 OBESE 25-30 OVERWEIGHT 18-25 NORMAL WEIGHT 18
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationMajor dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction
Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction Esther Lopez Garcia, Matthias B Schulze, Teresa T Fung, James B Meigs, Nader Rifai, JoAnn
More informationBREAST CANCER RISK ASSESSMENT AND PRIMARY PREVENTION FOR HIGH RISK PATIENTS, RACHEL CATHERINE JANKOWITZ, MD 1
FOR HIGH RISK PATIENTS, RACHEL CATHERINE JANKOWITZ, MD 1 Hello, my name is Rachel Jankowitz, I m an assistant professor of medicine in the Division of Hematology Oncology at the University of Pittsburgh
More informationOutline. Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment. Introduction. Current clinical practice
Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment Radiation Biology Outline Introduction: Predictive assays in radiation therapy Examples for specific tumors Immunotherapy Summary
More informationpatient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer
More informationTranslating DNA repair pathways into therapeutic targets: beyond the BRCA1/2 and PARP inhibitor saga. Jorge S Reis-Filho, MD PhD FRCPath
Translating DNA repair pathways into therapeutic targets: beyond the BRCA1/2 and PARP inhibitor saga Jorge S Reis-Filho, MD PhD FRCPath Summary How do PARP inhibitors work? Synthetic lethality Potential
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationOffice of Population Health Genomics
Office of Population Health Genomics Policy: Protocol for the management of female BRCA mutation carriers in Western Australia Purpose: Best Practice guidelines for the management of female BRCA mutation
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME
1 University of Papua New Guinea School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PBL SEMINAR INSULIN RESISTANCE, POLYCYSTIC OVARIAN
More informationPrevalence of microalbuminuria among sudanese type 2 diabetic patients at elmusbah center at ombadda - omdurman
IOSR Journal of Pharmacy ISSN: 2250-3013, www.iosrphr.org Volume 2 Issue 5 Sep-Oct. 2012 PP.51-55 Prevalence of microalbuminuria among sudanese type 2 diabetic patients at elmusbah center at ombadda -
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationImproving cardiometabolic health in Major Mental Illness
Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationWisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics
Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics In Situ Breast Cancer in Wisconsin INTRODUCTION This bulletin provides information
More informationPrevalence and risk factor of chronic kidney disease in elderly diabetic patients in Korea 성애병원 내과 김정한
Prevalence and risk factor of chronic kidney disease in elderly diabetic patients in Korea 성애병원 내과 김정한 Introduction CKD의 정의와 egfr의 측정 CKD의 risk factor와 mechanism 한국의 CKD prevalence 와 prognosis CKD의 치료와
More informationTreatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections.
National Diabetes Statistics What is diabetes? Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both.
More informationHow To Know If Low Protein Diet Is Beneficial For Kidney Health
Protein Intake and Diabetic Kidney Disease Robert C. Stanton Joslin Diabetes Center 1/Serum Creatinine Plot Low Protein Protects in Renal Ablation Model 24% Protein Diet 6% Protein Diet Right Nephrectomy
More informationPrescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital
Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI
More informationMen Sexual Dysfunction Associated with Obesity and Metabolic Syndrome
Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome By Aly A. Abbassy, MD, FACE Professor of Medicine (Endocrinology) Alexandria University My Talk will include: 1-Types of Men sexual
More informationDiagnosis, classification and prevention of diabetes
Diagnosis, classification and prevention of diabetes Section 1 1 of 4 Curriculum Module II 1 Diagnosis, classification and presentation of diabetes Slide 2 of 48 Polyurea Definition of diabetes Slide 3
More informationIntroduction. Pathogenesis of type 2 diabetes
Introduction Type 2 diabetes mellitus (t2dm) is the most prevalent form of diabetes worldwide. It is characterised by high fasting and high postprandial blood glucose concentrations (hyperglycemia). Chronic
More informationDevelopment of Bone Metastases in Men With Prostate Cancer
Development of Bone Metastases in Men With Prostate Cancer Explore the Causes Understand the Consequences Natural History of Prostate Cancer Progression Many prostate tumors may become castrate-resistant
More information1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
More informationMechanism Of Action of Palbociclib & PFS Benefit
A Phase II Randomized Controlled Trial of Palbociclib & Tamoxifen/Fulvestrant in Postmenopausal Women and Men With Hormone-Receptor Positive, HER2- Negative Metastatic Breast Cancer (MBC) Protocol Chair:
More informationPharmacogenetic Activities in SWOG Breast Cancer
Pharmacogenetic Activities in SWOG Breast Cancer Pharmacogenomics: Future Plans S8897 Adjuvant CMF vs. CAF/ no Treatment Ambrosone RO1: Other genes (TBCI approved, analyses ongoing) S0221 Adjuvant Dose
More informationThe Influence of Infant Health on Adult Chronic Disease
The Influence of Infant Health on Adult Chronic Disease Womb to Tomb Dr Clare MacVicar Introduction Many diseases in adulthood are related to growth patterns during early life Maternal nutrition important
More informationWhat is the reference cytotoxic regimen in advanced gastric cancer?
What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.
More informationLow dose capecitabine is effective and relatively nontoxic in breast cancer treatment.
1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300
More information